Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

As gene therapies continue to evolve as a promising frontier in medical treatment, regulatory scrutiny intensifies following safety concerns. Recent developments with Sarepta Therapeutics Inc (NASDAQ:SRPT) highlight the delicate balance between innovation and patient safety in the biopharmaceutical industry.

Benzinga

What's Going On With Eli Lilly Stock On Tuesday?

Eli Lilly and Co. (NYSE:LLY) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:NVO), trimmed its 2025 financial outlook.

Benzinga

Single-serve coffee pods sold at Costco, Walmart and Target recalled for potential contamination

The recalled coffee pods were sold in 10-count boxes

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

US health officials crack down on kratom-related products after complaints from supplement industry

U.S. health officials are cracking down on an opioid-like ingredient being added to drinks, supplements and other products

The Independent UK

These Analysts Increase Their Forecasts On PTC Therapeutics

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced it has gained FDA approval for SEPHIENCE on Monday.

Benzinga

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand

Incyte Corporation (NASDAQ:INCY) reported on Tuesday that its second-quarter revenue was $1.22 billion, up 16% year over year. The company beat the consensus of $1.15 billion.

Benzinga

AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook

AstraZeneca Plc (NASDAQ:AZN) on Tuesday reported second-quarter 2025 sales of $14.46 billion, up 12% year over year (+11% at constant currency), marginally beating the consensus of $14.07 billion, driven by double-digit growth in oncology and biopharmaceuticals.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Ozempic And Wegovy Maker Cuts Outlook In Surprise Move, Picks New CEO

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment Ozempic, experienced a significant downturn on Tuesday following the company’s decision to trim its 2025 financial outlook.

Benzinga

Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On?

Stock of Sarepta Therapeutics Inc. (NASDAQ:SRPT) surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration’s (FDA) recommendation to lift the voluntary hold on Elevidys, Sarepta’s gene therapy for Duchenne Muscular Dystrophy.

Benzinga

Are Chemical Sunscreens Safe? Here’s What the Latest Research Really Says

You’ve probably seen claims that chemical sunscreens are harmful—but what’s the real story behind those warnings? With buzz on social media and litigation around ingredients like oxybenzone, many wonder if they should switch. The latest science offers clarity: chemical filters are absorbed into the bloodstream—but current evidence doesn’t show this…

Clever Dude

Sarepta will resume gene therapy shipments after FDA review of recent patient death

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy

The Independent UK

Sarepta Therapeutics Stock Soars After FDA Removes Hold On Elevidys For Some Patients

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares were halted in extended trading Monday after the U.S. Food and Drug Administration (FDA) recommended the removal of a voluntary hold for Elevidys.

Benzinga

FDA Probes Death Of 8-Year-Old Who Received Sarepta's Elevidys

The U.S. Food and Drug Administration (FDA) announced on Friday, after market close, that it is investigating the death of an 8-year-old boy who had received Elevidys, Sarepta Therapeutics Inc.’s (NASDAQ:SRPT) gene therapy for Duchenne muscular dystrophy.

Benzinga

Weight-loss jab Wegovy sees another prescription boost after ban on copycats

Novo CEO ousted in May, in place until successor named

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Kiplinger

Trump Calls for Cane Sugar Coke: Will You Pay Higher Prices and Soda Tax?

The debate over cane sugar vs. corn syrup is heating up, raising questions about cost, policy, and, in some cases, soda taxes.

The Independent UK

NIH cuts spotlight a hidden crisis facing patients with experimental brain implants

People with experimental brain implants often turn to the treatment as a last resort, hoping to improve their health when everything else has failed

Grocery Coupon Guide

9 Amazon Products That Sparked Legal Investigations

Amazon is everywhere. You can buy almost anything with a few clicks. But not every product on Amazon is as safe or legal as it seems. Some items have led to lawsuits, government warnings, and even criminal charges. These cases matter because they show how online shopping can go wrong.…

Benzinga

Benzinga Bulls And Bears: T-Mobile, LendingTree, Molina Healthcare — And Trade Deal Optimism Boosts Markets

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Married couple whose home was bursting with truckloads of illegal sex pills sentenced

Eduard Yusupov and Diana Fuzailov sold sexual enhancement products online via their company Love Potion, Inc., claiming them to be made from natural ingredients

Benzinga

Congress Sounds Alarm Over Illegal Weight-Loss Drug Imports From China

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

Benzinga

Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

Benzinga

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

On Friday, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a negative opinion on the conditional marketing authorisation (CMA) for Elevidys (delandistrogene moxeparvovec) for ambulatory individuals aged three to seven years with Duchenne muscular dystrophy (DMD).

Benzinga

Eli Lilly's Early Alzheimer's Drug Recommended For Approval By European Drug Regulator's Panel

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Friday recommending Eli Lilly and Co.’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease in adults with confirmed amyloid pathology who are apolipoprotein E ε4 (ApoE4) heterozygotes or non-carriers.

Everybody Loves Your Money

9 DIY Remedies That Medical Boards Are Warning Against

DIY health hacks flood social media and blogs with promises of miracle cures and quick fixes. From homemade detox teas to sketchy dental work, these trends often spread faster than facts can catch up. But while some may seem harmless, medical boards across the country are issuing clear warnings.

The Guardian - US

RFK Jr wants bright artificial dyes out of food. Are Americans ready to let go?

In the past, US consumers have resisted their favorite foods changing to natural dyes. Attitudes might shift if Maha converts the entire industry

1 … 65 66 67 68

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.